Cash & Equivalents
Merck & Co. Cash & Equivalents decreased by 19.6% to $14.69B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.3%, from $13.32B to $14.69B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 12.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.63B | $10.05B | $8.17B | $8.61B | $9.75B | $11.28B | $12.77B | $9.79B | $5.71B | $8.67B | $6.91B | $5.67B | $11.37B | $14.69B | $13.32B | $8.73B | $8.07B | $18.26B | $14.69B |
| QoQ Change | — | +16.4% | -18.7% | +5.5% | +13.2% | +15.6% | +13.2% | -23.4% | -41.6% | +51.8% | -20.3% | -17.9% | +100.5% | +29.1% | -9.3% | -34.4% | -7.5% | +126.2% | -19.6% |
| YoY Change | — | — | — | — | +13.0% | +12.3% | +56.4% | +13.6% | -41.4% | -23.1% | -45.9% | -42.0% | +99.1% | +69.4% | +92.8% | +54.0% | -29.0% | +24.3% | +10.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s cash & equivalents?
- Merck & Co. (MRK) reported cash & equivalents of $14.69B in Q4 2025.
- How has Merck & Co.'s cash & equivalents changed year-over-year?
- Merck & Co.'s cash & equivalents increased by 10.3% year-over-year, from $13.32B to $14.69B.
- What is the long-term trend for Merck & Co.'s cash & equivalents?
- Over 5 years (2020 to 2025), Merck & Co.'s cash & equivalents has grown at a 12.5% compound annual growth rate (CAGR), from $8.17B to $14.69B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.